Study procedures | Baseline | Treatment period | Follow-up period | |
---|---|---|---|---|
Time point | 0 | 3-month | 6-month | 12-month |
Outcome measures | Â | Â | Â | Â |
Clinical data | √ |  |  |  |
Coronary artery CT | √ |  | √ |  |
CRP | √ |  | √ |  |
Therapeutic evaluation | ||||
 Blood lipids | √ |  | √ |  |
 SAQ | √ | √ | √ | √ |
 Scores of CM symptoms | √ | √ | √ | √ |
 ALT, AST | √ |  | √ |  |
 Creatinine, blood urea nitrogen | √ |  | √ |  |
Safety indicators | ||||
 Blood glucose | √ |  | √ |  |
 Drug interaction | √ | √ | √ | √ |
 Adverse event |  | √ | √ | √ |
 Compliance observation |  | √ | √ | √ |
 Medicine treatment | √ | √ | √ | √ |